Login or Register to unlock everything MedSchool has to offer!

Monoclonal Antibodies

 
 
 
Immunotherapy
Haematologic Malignancies
Solid Organ Malignancies
Other
 
 

Anti-CTLA4 Antibodies

 
 
  •  
    IV infusion
    Ipilimumab
    Yervoy 
    • Mechanism of Action
    • A monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4), a T cell inhibitory molecule that binds to B7 and prevents its binding to CD28.
    • The B7 : CD28 complex normally potentiates the binding of T cell receptors to MHC/antigen complexes on antigen-presenting cells, stimulating T cell proliferation and differentiation.
    • CTLA-4 is expressed on the surface of T cells after activation, and provides inhibitory signalling to T cells by binding B7.
    • Binding to anti-CTLA-4 antibodies to CTLA-4 leaves B7 free to continue to bind to CD28 and provide ongoing T cell costimulation.

Clinical Use

    • Indications
    • Unresectable or metastatic melanoma
    • Intermediate / poor risk advanced renal cell carcinoma
    • Adverse Effects
    • Immune-Related
    • Endocrinopathies - hypopituitarism, hypothyroidism, adrenal insufficiency
    • GI toxicity - colitis
    • Hepatotoxicity - LFT derangement
    • Skin - rash / pruritis
    • Other
    • Nausea / vomiting / diarrhoea
    • Fatigue
    • Headache
    • Tremor
    • Cough
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
Read More...
Feedback